Structure-guided discovery of potent and dual-acting human parainfluenza virus haemagglutinin-neuraminidase inhibitors

Nature Communications

Volumn 5, Issue , 2014, Pages

  Guillon, Patrice ^a   Dirr, Larissa ^a   El Deeb, Ibrahim M ^a   Winger, Moritz ^a   Bailly, Benjamin ^a   Haselhorst, Thomas ^a   Dyason, Jeffrey C ^a   Von Itzstein, Mark ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INFLUENZA VIRUS HEMAGGLUTININ; PARAINFLUENZA VIRUS HEMAGGLUTININ; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ENZYME INHIBITOR; NEURAMINIC ACID DERIVATIVE; RECOMBINANT PROTEIN; SIALIDASE; SOLVENT; VIRUS HEMAGGLUTININ;

CHILD HEALTH; DRUG DEVELOPMENT; HOSPITAL SECTOR; INFLUENZA; INHIBITOR; NUCLEAR MAGNETIC RESONANCE; VIRUS;

ARTICLE; DRUG STRUCTURE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARAMYXOVIRINAE; VIRION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPUTER SIMULATION; CONFORMATION; DRUG DESIGN; ENZYME ACTIVE SITE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMAN; HUMAN PARAINFLUENZA VIRUS 3; IC50; MOLECULAR DYNAMICS; SURFACE PROPERTY; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

PARAINFLUENZA VIRUS;

ANTIVIRAL AGENTS; CATALYTIC DOMAIN; CELL LINE, TUMOR; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HEMAGGLUTININS, VIRAL; HUMANS; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR CONFORMATION; MOLECULAR DYNAMICS SIMULATION; NEURAMINIC ACIDS; NEURAMINIDASE; PARAINFLUENZA VIRUS 3, HUMAN; RECOMBINANT PROTEINS; SOLVENTS; SURFACE PROPERTIES;

EID: 84923378919     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6268     Document Type: Article

References (58)

1. Henrickson, K. J. Parainfluenza viruses. Clin. Microbiol. Rev. 16, 242-264 (2003).
2. Glezen, W. P. & Denny, F. W. in Viral Infection of Humans: Epidemiology and Control 4th edn, Ch. 19 ( eds Evans, A. S. & Kaslow, R. A.) 551-568 (Plenum Press, 1997).
3. Nichols, W. G., Peck Campbell, A. J. & Boeckh, M. Respiratory viruses other than influenza virus: impact and therapeutic advances. Clin. Microbiol. Rev. 21, 274-290 (2008).
4. Reed, G., Jewett, P. H., Thompson, J., Tollefson, S. & Wright, P. F. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children <5 years old. J. Infect. Dis. 175, 807-813 (1997).
5. Heilman, C. A. From the National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses. J. Infect. Dis. 161, 402-406 (1990).
6. Henrickson, K. J., Kuhn, S. M. & Savatski, L. L. Epidemiology and cost of infection with human parainfluenza virus types 1 and 2 in young children. Clin. Infect. Dis. 18, 770-779 (1994).
7. Denny, F. W. & Clyde, W. A. J. Acute lower respiratory tract infections in non-hospitalized children. J. Pediatr. 108, 635-646 (1986).
8. Sato, M. & Wright, P. F. Current status of vaccines for parainfluenza virus infections. Pediatr. Infect. Dis. J. 27, S123-S125 (2008).
9. De La Mora, P. & Moscona, A. A daring treatment and a successful outcome: the need for targeted therapies for pediatric respiratory viruses. Pediatr. Transplant. 11, 121-123 (2007).
10. Karron, R. A. et al. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children. Vaccine 30, 3975-3981 (2012).
11. Moscona, A. et al. A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo. J. Infect. Dis. 202, 234-241 (2010).
12. Porotto, M., Palmer, S. G., Palermo, L. M. & Moscona, A. Mechanism of fusion triggering by human parainfluenza virus type III: communication between viral glycoproteins during entry. J. Biol. Chem. 287, 778-793 (2012).
13. Moscona, A. Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease. J. Clin. Invest. 115, 1688-1698 (2005).
14. Amonsen, M., Smith, D. F., Cummings, R. D. & Air, G. M. Human parainfluenza viruses hPIV1 and hPIV3 bind oligosaccharides with alpha2-3-linked sialic acids that are distinct from those bound by H5 avian influenza virus hemagglutinin. J. Virol. 81, 8341-8345 (2007).
15. Song, X. et al. A sialylated glycan microarray reveals novel interactions of modified sialic acids with proteins and viruses. J. Biol. Chem. 286, 31610-31622 (2011).
16. Alymova, I. V. et al. Receptor-binding specificity of the human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein. Glycobiology 22, 174-180 (2012).
17. Palermo, L. M., Porotto, M., Greengard, O. & Moscona, A. Fusion promotion by a paramyxovirus hemagglutinin-neuraminidase protein: pH modulation of receptor avidity of binding sites I and II. J. Virol. 81, 9152-9161 (2007).
18. Alymova, I. V. et al. Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo. Antimicrob. Agents Chemother. 48, 1495-1502 (2004).
19. Tindal, D. J. et al. Synthesis and evaluation of 4-O-alkylated 2-deoxy-2,3-didehydro-N-acetylneuraminic acid derivatives as inhibitors of human parainfluenza virus type-3 sialidase activity. Bioorg. Med. Chem. Lett. 17, 1655-1658 (2007).
20. Alymova, I. V. et al. Efficacy of the novel parainfluenza virus haemagglutinin-neuraminidase inhibitor BCX 2798 in mice - Further evaluation. Antivir. Ther. 14, 891-898 (2009).
21. Watanabe, M. et al. Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice. Antimicrob. Agents Chemother. 53, 3942-3951 (2009).
22. Nishino, R. et al. Syntheses of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid analogues modified by N-sulfonylamidino groups at the C-4 position and biological evaluation as inhibitors of human parainfluenza virus type 1. Bioorg. Med. Chem. 19, 2418-2427 (2011).
23. Nishino, R. et al. Syntheses of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid analogues modified by α-acylaminoamido groups at the C-4 position using isocyanide-based four-component coupling and biological evaluation as inhibitors of human parainfluenza virus type 1. Chem. Pharm. Bull. (Tokyo) 61, 69-74 (2013).
24. Winger, M. & von Itzstein, M. Exposing the flexibility of human parainfluenza virus hemagglutinin-neuraminidase. J. Am. Chem. Soc. 34, 18447-18452 (2012).
25. Lawrence, M. C. et al. Structure of the haemagglutinin-neuraminidase from human parainfluenza virus type III. J. Mol. Biol. 335, 1343-1357 (2004).
26. von Itzstein, M., Jin, B., Wu, W.-Y. & Chandler, M. A convenient method for the introduction of nitrogen and sulfur at C-4 on a sialic acid analogue. Carbohydr. Res. 244, 181-185 (1993).
27. Lu, Y. & Gervay-Hague, J. Synthesis of C-4 and C-7 triazole analogs of zanamivir as multivalent sialic acid containing scaffolds. Carbohydr. Res. 342, 1636-1650 (2007).
28. Li, J. et al. Syntheses of triazole-modified zanamivir analogues via click chemistry and anti-AIV activities. Bioorg. Med. Chem. Lett. 16, 5009-5013 (2006).
29. Chand, P., Babu, Y. S., Rowland, S. R. & Lin, T.-H. Preparation of neuraminic acids and analogs useful for inhibiting paramyxovirus neuraminidase. PCT application WO2002076971 (2002).
30. Potier, M., Mameli, L., Bélisle, M., Dallaire, L. & Melançon, S. B. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. Anal. Biochem. 94, 287-296 (1979).
31. Greengard, O., Poltoratskaia, N., Leikina, E., Zimmerberg, J. & Moscona, A. The anti-influenza virus agent 4-GU-DANA (zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA. J. Virol. 74, 11108-11114 (2000).
32. Suzuki, T. et al. Inhibition of human parainfluenza virus type 1 sialidase by analogs of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid. Glycoconj. J. 18, 331-337 (2001).
33. Suzuki, T. et al. Receptor specificities of human respiroviruses. J. Virol. 75, 4604-4613 (2001).
34. Varki, A. Loss of N-glycolylneuraminic acid in humans: mechanisms, consequences, and implications for hominid evolution. Am. J. Phys. Anthropol. 116, 54-69 (2001).
35. Bradley, K. C. et al. Analysis of influenza virus hemagglutinin receptor binding mutants with limited receptor recognition properties and conditional replication characteristics. J. Virol. 85, 12387-12398 (2011).
36. Zhao, H., De, B. P., Das, T. & Banerjee, A. K. Inhibition of human parainfluenza virus-3 replication by interferon and human MxA. Virology 220, 330-338 (1996).
37. van Gunsteren, W. F. et al. Biomolecular Simulation: The GROMOS Manual and User Guide (vdf Hochschulverlag, ETH Zürich, 1996).
38. Scott, W. R. P. et al. The GROMOS biomolecular simulation program package. J. Phys. Chem. A 103, 3596-3607 (1999).
39. Schmid, N. et al. Definition and testing of the GROMOS force-field versions: 54A7 and 54B7. Eur. Biophys. J. 40, 843-856 (2011).
40. Oostenbrink, C., Villa, A., Mark, A. E. & van Gunsteren, W. F. A biomolecular force field based on the free enthalpy of hydration and solvation: the GROMOS force-field parameter sets 53A5 and 53A6. J. Comput. Chem. 25, 1656-1676 (2004).
41. Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F. & Hermans, J. in Intermolecular Forces (ed. Pullman, B.) 331-342 (Reidel, 1981).
42. Ryckaert, J.-P., Ciccotti, G. & Berendsen, H. J. C. Numerical integration of cartesian equations of motion of a system with constraints - molecular dynamics of n-alkanes. J. Comput. Phys. 23, 327-341 (1977).
43. Tironi, I. G., Sperb, R., Smith, P. E. & van Gunsteren, W. F. A generalized reaction field method for molecular dynamics simulations. J. Chem. Phys. 102, 5451-5459 (1995).
44. Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F., Di Nola, A. & Haak, J. R. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 81, 3684-3690 (1984).
45. Christen, M. et al. The GROMOS software for biomolecular simulation: GROMOS05. J. Comput. Chem. 26, 1719-1751 (2005).
46. Daura, X., Jaun, B., Seebach, D., van Gunsteren, W. F. & Mark, A. E. Reversible peptide folding in solution by molecular dynamics simulation. J. Mol. Biol. 280, 925-932 (1998).
47. Wallace, A. C., Laskowski, R. A. & Thornton, J. M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 8, 127-134 (1996).
48. Durrant, J. D., de Oliveira, C. A. F. & McCammon, J. A. POVME: an algorithm for measuring binding-pocket volumes. J. Mol. Graphics Modell. 29, 773-776 (2011).
49. Furuhata, K., Sato, S., Goto, M., Takayanagi, H. & Ogura, H. Studies on sialic acids. VII. The crystal and molecular structure of N-acetyl-2,3-dehydro-2-deoxyneuraminic acid. Chem. Pharm. Bull. 36, 1872-1876 (1988).
50. Holzer, C. T. et al. Inhibition of sialidases from viral, bacterial and mammalian sources by analogues of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid modified at the C-4 position. Glycoconj. J. 10, 40-44 (1993).
51. Matrosovich, M., Matrosovich, T., Garten, W. & Klenk, H.-D. New low-viscosity overlay medium for viral plaque assays. Virol. J. 3, 63 (2006).
52. Berkowitz, F. E. & Levin, M. J. Use of an enzyme-linked immunosorbent assay performed directly on fixed infected cell monolayers for evaluating drugs against varicella-zoster virus. Antimicrob. Agents Chemother. 28, 207-210 (1985).
53. Ståhle, E. L. et al. Solid phase ELISA for determination of the virus dose dependent sensitivity of human cytomegalovirus to antiviral drugs in vitro. Antiviral Res. 40, 105-112 (1998).
54. Myc, A., Anderson, M. J. & Baker, Jr J. R. Optimization of in situ cellular ELISA performed on influenza A virus-infected monolayers for screening of antiviral agents. J. Virol. Methods 77, 165-177 (1999).
55. Koishi, A. C., Zanello, P. R., Bianco, É. M., Bordignon, J. & Nunes Duarte dos Santos, C. Screening of dengue virus antiviral activity of marine seaweeds by an in situ enzyme-linked immunosorbent assay. PLoS ONE 7, e51089 (2012).
56. Mayer, M. & Meyer, B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem. Int. Ed. 38, 1784-1788 (1999).
57. Mayer, M. & Meyer, B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J. Am. Chem. Soc. 123, 6108-6117 (2001).
58. Haselhorst, T. et al. Recognition of the GM3 ganglioside glycan by Rhesus rotavirus particles. Angew. Chem. Int. Ed. 50, 1055-1058 (2011).